NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its earnings results on Thursday, February, 6th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.59 by $0.06. The biotechnology company had revenue of $52.57 million for the quarter, compared to analyst estimates of $58.75 million. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The firm's quarterly revenue was down 24.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.25 EPS. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 brokers have issued 1 year target prices for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $101.33 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Headlines about ENTA stock have been trending very negative on Monday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Enanta Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Nektar Therapeutics (NKTR), Evotec (EVTCY), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), SAGE Therapeutics (SAGE), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Emergent Biosolutions (EBS) and Genmab A/S (GMAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), Wells Fargo & Co (WFC), NVIDIA (NVDA), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (8.83%), State Street Corp (4.19%), Renaissance Technologies LLC (3.69%), Janus Henderson Group PLC (3.22%), Krensavage Asset Management LLC (2.46%) and Acadian Asset Management LLC (1.74%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, State Street Corp, FMR LLC, Marshall Wace North America L.P., Baird Financial Group Inc., AQR Capital Management LLC, Rafferty Asset Management LLC and Alliancebernstein L.P.. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Fairmount Funds Management LLC, Renaissance Technologies LLC, Goldman Sachs Group Inc., Prudential Financial Inc., California Public Employees Retirement System, AJO LP and Aviva PLC. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $53.20.

Enanta Pharmaceuticals has a market capitalization of $1.06 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]